Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 12
2003 21
2004 16
2005 18
2006 17
2007 12
2008 21
2009 19
2010 15
2011 33
2012 21
2013 12
2014 12
2015 16
2016 13
2017 16
2018 16
2019 10
2020 7
2021 10
2022 4
2023 3
2024 2
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

292 results

Results by year

Filters applied: . Clear all
Page 1
Effect of spironolactone wash-out on albuminuria after long-term treatment in individuals with type 2 diabetes and high risk of kidney disease-An observational follow-up of the PRIORITY study.
Wasehuus V, Rotbain Curovic V, Tofte N, Lindhardt M, Currie G, Delles C, Frimodt-Møller M, Mischak H, von der Leyen H, Hansen TW, Kümler T, Persson F, Rossing P; PRIORITY Study group. Wasehuus V, et al. Diabetes Obes Metab. 2025 Jan;27(1):387-393. doi: 10.1111/dom.16037. Epub 2024 Oct 28. Diabetes Obes Metab. 2025. PMID: 39468380 Clinical Trial.
Extracellular matrix turnover proteins as risk markers in people with type 2 diabetes and microalbuminuria.
Skriver-Møller AC, Møller AL, Blond MB, Rasmussen DGK, Genovese F, Reinhard H, von Scholten BJ, Jacobsen PK, Parving HH, Karsdal MA, Hansen TW, Rossing P. Skriver-Møller AC, et al. Among authors: parving hh. J Diabetes Complications. 2024 Jun;38(6):108765. doi: 10.1016/j.jdiacomp.2024.108765. Epub 2024 May 7. J Diabetes Complications. 2024. PMID: 38749295
The Effect of Insulin Degludec Versus Insulin Glargine U100 on Glucose Metrics Recorded During Continuous Glucose Monitoring in People With Type 1 Diabetes and Recurrent Nocturnal Severe Hypoglycemia.
Brøsen JMB, Agesen RM, Alibegovic AC, Andersen HU, Beck-Nielsen H, Gustenhoff P, Hansen TK, Hedetoft C, Jensen TJ, Juhl CB, Stolberg CR, Lerche SS, Nørgaard K, Parving HH, Tarnow L, Thorsteinsson B, Pedersen-Bjergaard U. Brøsen JMB, et al. Among authors: parving hh. J Diabetes Sci Technol. 2025 Mar;19(2):390-399. doi: 10.1177/19322968231197423. Epub 2023 Sep 6. J Diabetes Sci Technol. 2025. PMID: 37671755 Free PMC article. Clinical Trial.
Marker for kidney fibrosis is associated with inflammation and deterioration of kidney function in people with type 2 diabetes and microalbuminuria.
Poulsen CG, Rasmussen DGK, Genovese F, Hansen TW, Nielsen SH, Reinhard H, von Scholten BJ, Jacobsen PK, Parving HH, Karsdal MA, Rossing P, Frimodt-Møller M. Poulsen CG, et al. Among authors: parving hh. PLoS One. 2023 Mar 17;18(3):e0283296. doi: 10.1371/journal.pone.0283296. eCollection 2023. PLoS One. 2023. PMID: 36930632 Free PMC article.
Effect of insulin degludec versus insulin glargine U100 on nocturnal glycaemia assessed by plasma glucose profiles in people with type 1 diabetes prone to nocturnal severe hypoglycaemia.
Brøsen JMB, Agesen RM, Kristensen PL, Alibegovic AC, Andersen HU, Beck-Nielsen H, Gustenhoff P, Hansen TK, Hedetoft C, Jensen T, Stolberg CR, Juhl CB, Lerche SS, Nørgaard K, Parving HH, Tarnow L, Thorsteinsson B, Pedersen-Bjergaard U. Brøsen JMB, et al. Among authors: parving hh. Diabetes Obes Metab. 2023 Jun;25(6):1557-1565. doi: 10.1111/dom.15003. Epub 2023 Feb 28. Diabetes Obes Metab. 2023. PMID: 36749303 Clinical Trial.
Organic Anion Transporter Gene Variants Associated With Plasma Exposure and Long-Term Response to Atrasentan in Patients With Diabetic Kidney Disease.
Smeijer JD, Koomen JV, Kohan DE, McMurray JJV, Bakris GL, Correa-Rotter R, Hou FF, Kitzman DW, Makino H, Mayer G, Nowicki M, Perkovic V, Rossing P, Tobe S, Parving HH, de Zeeuw D, Heerspink HJL. Smeijer JD, et al. Among authors: parving hh. Clin Pharmacol Ther. 2022 Nov;112(5):1098-1107. doi: 10.1002/cpt.2721. Epub 2022 Aug 11. Clin Pharmacol Ther. 2022. PMID: 35892316 Free PMC article. Clinical Trial.
Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure.
Smeijer JD, Koomen J, Kohan DE, McMurray JJV, Bakris GL, Correa-Rotter R, Hou FF, Januzzi JL, Kitzman DW, Kolansky DM, Makino H, Perkovic V, Tobe S, Parving HH, de Zeeuw D, Heerspink HJL. Smeijer JD, et al. Among authors: parving hh. JACC Heart Fail. 2022 Jul;10(7):498-507. doi: 10.1016/j.jchf.2022.03.004. Epub 2022 May 4. JACC Heart Fail. 2022. PMID: 35772861 Free article. Clinical Trial.
Continuous Glucose Monitoring-Recorded Hypoglycemia with Insulin Degludec or Insulin Glargine U100 in People with Type 1 Diabetes Prone to Nocturnal Severe Hypoglycemia.
Brøsen JMB, Agesen RM, Alibegovic AC, Ullits Andersen H, Beck-Nielsen H, Gustenhoff P, Krarup Hansen T, Hedetoft CGR, Jensen TJ, Stolberg CR, Bogh Juhl C, Lerche SS, Nørgaard K, Parving HH, Tarnow L, Thorsteinsson B, Pedersen-Bjergaard U. Brøsen JMB, et al. Among authors: parving hh. Diabetes Technol Ther. 2022 Sep;24(9):643-654. doi: 10.1089/dia.2021.0567. Epub 2022 Jun 22. Diabetes Technol Ther. 2022. PMID: 35467938 Clinical Trial.
The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A Post Hoc Analysis of the SONAR Randomized Trial.
Waijer SW, Gansevoort RT, Bakris GL, Correa-Rotter R, Hou FF, Kohan DE, Kitzman DW, Makino H, McMurray JJV, Perkovic V, Tobe S, Parving HH, de Zeeuw D, Heerspink HJL. Waijer SW, et al. Among authors: parving hh. Clin J Am Soc Nephrol. 2021 Dec;16(12):1824-1832. doi: 10.2215/CJN.07340521. Epub 2021 Dec 1. Clin J Am Soc Nephrol. 2021. PMID: 34853062 Free PMC article. Clinical Trial.
Comparison of treatment with insulin degludec and glargine U100 in patients with type 1 diabetes prone to nocturnal severe hypoglycaemia: The HypoDeg randomized, controlled, open-label, crossover trial.
Pedersen-Bjergaard U, Agesen RM, Brøsen JMB, Alibegovic AC, Andersen HU, Beck-Nielsen H, Gustenhoff P, Hansen TK, Hedetoft C, Jensen TJ, Juhl CB, Jensen AK, Lerche SS, Nørgaard K, Parving HH, Sørensen AL, Tarnow L, Thorsteinsson B. Pedersen-Bjergaard U, et al. Among authors: parving hh. Diabetes Obes Metab. 2022 Feb;24(2):257-267. doi: 10.1111/dom.14574. Epub 2021 Nov 2. Diabetes Obes Metab. 2022. PMID: 34643020 Free PMC article. Clinical Trial.
292 results